NCT01872442已完成2 期
Combination of Dasatinib and Peg-Interferon Alpha 2b in First Line for Chronic Myeloid Leukemia in Chronic Phase
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 主要终点
- Cumulative rate of molecular response
研究概览
简要总结
Interferon alpha was a therapy used in Chronic Myeloid Leukemia in Chronic phase prior to the advent of tyrosine kinase inhibitors. Synergistic effect of the combination of Peg-IFNα2a with Imatinib was demonstrated in the clinical SPIRIT trial. In this study, the investigators address the question of the efficacy and safety of dasatinib in combination with low dose of Peg-IFNα-2b as frontline therapy for patients with newly diagnosed Chronic Myeloid Leukemia in Chronic phase.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed Written Informed Consent.
- •Target Population
- •a)18 to 65 years b)Newly diagnosed (≤ 3 months) Philadelphia chromosome positive chronic CP-CML c)Major BCR-ABL transcripts d)Not previously treated for CML except with hydroxyurea or anagrelide e)ECOG Performance Status≤ 2 f)Adequate Organ Function. i)Total bilirubin< 2.0 times the institutional Upper Limit of Normal ii)Hepatic enzymes(AST, ALT )≤ 2.5 ULN iii)Serum Na, K+, Mg2+ and Ca2+ > Lower Limit of Normal (LLN) or supplemented iv)Serum Creatinine< 1.5 ULN g)Women of childbearing potential (WOCBP) must be using an adequate method of contraception.
- •Free subject, without guardianship nor subordination,
- •Health insurance coverage. -
排除标准
- •Patients with BCR-ABL other than M-BCR-ABL, Philadelphia negative CML.
- •Patients previously treated with Tyrosine Kinase Inhibitors (TKIs).
- •Medical history and concurrent diseases :
- •Hypersensitivity to any of the excipients of dasatinib
- •Prior treatment with Interferon-α, contraindication to interferon-α, hypersensitivity to any of the excipients of PegIFNα2b,
- •Concomitant immunosuppressive treatment or corticosteroids,
- •Preexisting thyroid disease unless it is controlled with conventional treatment, Auto-immune thyroiditis,
- •Autoimmune disorder, Chronic liver disease,
- •Prior or ongoing severe psychiatric disease,
- •Epilepsy or compromised central nervous system(CNS) function,
- •HIV positivity, chronic hepatitis B or C,
- •Uncontrolled or significant cardio vascular or pulmonary disease,
- •i)Uncontrolled angina, myocardial infarction or congestive heart failure within 6 months, ii)Echocardiography with LVF < 45% or LLN, peak velocity of tricuspid regurgitant flow > 2,8 m/s iii)Pulmonary arterial hypertension (PAH), iv)Any history of clinically significant ventricular or supraventricular arrhythmias, v)Diagnosed congenital long QT syndrome, vi)Prolonged QTc interval > 450 msec (Fredericia) on 3 pre-entry electrocardiogram, vii)Subjects with hypokalemia or hypomagnesemia if it cannot be corrected, j)Other malignant disease during the last 5 years prior to the inclusion except basal cell carcinoma of the skin or carcinoma in situ of the cervix, k)History of significant bleeding disorder unrelated to CML, including: i)Diagnosed congenital bleeding disorders (e.g. von Willebrand's disease), ii)Ongoing or recent (≤ 3 months) significant gastrointestinal bleeding. l)Another severe or life -threatening medical disease.
- •Women who are pregnant or breastfeeding, WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for at least 4 weeks after the last dose of study drug.
- •Prohibited treatments and/or therapies:
- •strong inhibitors of the CYP3A4,
- •category I drugs that are generally accepted to have a risk of causing "Torsades de Pointes", Patients must discontinue the drug minimum 7 days prior to starting dasatinib.
- •History /any condition for poor compliance to the treatment.
- •Inability to freely provide consent through judiciary or administrative condition.
- •Ongoing participation to another study.
研究组 & 干预措施
Dasatinib
Experimental
Dasatinib,Bristol Myers Squibb
干预措施: Peg-Interferon alpha2b (Drug)
Dasatinib
Experimental
Dasatinib,Bristol Myers Squibb
干预措施: Dasatinib (Drug)
Peg-Interferon alpha2b
Experimental
Peg-Interferon alpha2b (Peg-IFN α2b), Merck
干预措施: Dasatinib (Drug)
Peg-Interferon alpha2b
Experimental
Peg-Interferon alpha2b (Peg-IFN α2b), Merck
干预措施: Peg-Interferon alpha2b (Drug)
结局指标
主要结局
Cumulative rate of molecular response
时间窗: at 12 months.
Molecular response 4.5 (MR4.5) is defined by either a positive BCR-ABL/ABL ratio ≤ 0.0032 on the international scale or by undetectable BCR-ABL with the analysis of at least 32000 copies of ABL (according to the ELN recommendations by N. Cross et al., leukemia 2012). Centralized analyses of molecular response by RTQPCR will be performed for all molecular assessments in this study.
次要结局
- Rate of complete cytogenetic response(3, 6, 12, 18, 24 months, and every 12 months thereafter.)
- Rate of major molecular responses(3, 6, 9, 12, 15, 18, 21, 24 months and every 6 months thereafter.)
- Rate of molecular response(6, 9, 12, 15, 18, 21, 24 months and every 6 months thereafter.)
- Kinetics and duration(6, 9, 12, 15, 18, 21, 24 months and every 6 months thereafter)
- Rate of PegIFN-α2b and dasatinib discontinuation(24 months)
研究者
相似试验
进行中（未招募）
不适用
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome PositiveAcute Lymphoblastic Leukemic Subjects Who are Experiencing Clinical Benefit onCurrent START or CA180039 Protocols: Long Term Safety and Efficacy Analysis.Revised Protocol Number 02 incorporating Administrative Letter 01 and Amendments 03 and 06 (v1.0, dated 24-Nov-2009)Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects.MedDRA version: 9.1Level: LLTClassification code 10009012Term: Chronic myelogenous leukemiaMedDRA version: 9.1Level: LLTClassification code 10034877Term: Philadelphia chromosome positiveMedDRA version: 9.1Level: LLTClassification code 10000845Term: Acute lymphoblastic leukemiaEUCTR2007-003624-37-FIBristol Myers Squibb International Corporation313
进行中（未招募）
不适用
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome PositiveAcute Lymphoblastic Leukemic Subjects Who are Experiencing Clinical Benefit onCurrent START Protocols: Long Term Safety and Efficacy Analysis.EUCTR2007-003624-37-IEBristol Myers Squibb International Corporation313
进行中（未招募）
不适用
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome PositiveAcute Lymphoblastic Leukemic Subjects Who are Experiencing Clinical Benefit onCurrent START Protocols: Long Term Safety and Efficacy Analysis.Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects.MedDRA version: 9.1Level: LLTClassification code 10009012Term: Chronic myelogenous leukemiaMedDRA version: 9.1Level: LLTClassification code 10034877Term: Philadelphia chromosome positiveMedDRA version: 9.1Level: LLTClassification code 10000845Term: Acute lymphoblastic leukemiaEUCTR2007-003624-37-HUBristol Myers Squibb International Corporation313
进行中（未招募）
不适用
Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome PositiveAcute Lymphoblastic Leukemic Subjects Who are Experiencing Clinical Benefit onCurrent START or CA180039 Protocols: Long Term Safety and Efficacy Analysis.Revised Protocol Number 02 incorporating Administrative Letter 01 and Amendment 03 & 06 (v1.0, dated 24-Nov-2009)EUCTR2007-003624-37-DEBristol Myers Squibb International Corporation313
进行中（未招募）
不适用
Chronic Myelogenous Leukemia or Philadelphia Chromosome PositiveAcute Lymphoblastic Leukemic Subjects who were previously enrolledand treated with dasatinib or imatinib in the START or CA180039protocols who are experiencing clinical benefit. The primary objective isto determine the long term safety and tolerability of treatment withdasatinibEUCTR2007-003624-37-GBBristol-Myers Squibb International Corporation313